Status:
NOT_YET_RECRUITING
Transcranial Magnetic Stimulation to Treat Prolonged Grief Disorder
Lead Sponsor:
Bruyère Health Research Institute.
Conditions:
Prolonged Grief Disorder
Complicated Grief
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Grief is a normal response after the death of a loved one. With time, the grief response decreases and people learn to cope with their loss. However, for some, the response becomes more intense and di...
Detailed Description
Prolonged Grief Disorder (PGD) is an important challenge among bereaved individuals. While the grief response following loss is typically acute, with symptoms diminishing over time, it can sometimes l...
Eligibility Criteria
Inclusion
- Bereaved individuals \>/= 18 years of age
- Score \>25 on the Inventory of Complicated Grief
- Must have a primary care physician
- Ability to understand and communicate in English
- Ability to provide first-person informed consent
Exclusion
- Current or previously diagnosed seizure disorder
- Documented brain lesions
- Contraindications to TMS (i.e., metallic skull plates, clips, stimulators, pacemakers)
- Current substance abuse disorder (e.g., schizophrenia)
- Pregnancy or lactation, or trying to conceive
- Advanced, incurable illness with an expected prognosis of \<3 months - bereaved family members are known to be at elevated risk of death from medical illness, but if death is expected in the near future, it would be difficult to justify using an entire week of their limited time for an unproven therapy.
Key Trial Info
Start Date :
July 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT06953596
Start Date
July 1 2025
End Date
April 30 2026
Last Update
May 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bruyere Health
Ottawa, Ontario, Canada, K1R 7A5